Known central nervous system involvement by PTCL
Patients with evidence of current central nervous system leukemic involvement
Central nervous system involvement
Presence of active/uncontrolled central nervous system involvement
Patients with any central nervous system involvement or CTCL.
Central nervous system involvement
Central nervous system involvement by lymphoma, including leptomeningeal involvement
EXCLUSION - INFUSION: Patients with central nervous system involvement
Myeloma-related central nervous system involvement
Central nervous system involvement
Central nervous system involvement with lymphoma at any time in the patient’s history; intrathecal prophylaxis during induction is allowed as long as active disease has not been identified
Suggestive central nervous system involvement with leukemia
Central nervous system involvement
Symptomatic central nervous system involvement.
Central nervous system involvement.
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)
Evidence of lymphoma outside of the central nervous system\r\n* Ocular involvement will not exclude
Known central nervous system involvement
Known active involvement of the central nervous system by lymphoma or leukemia
Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement
Has either clinical evidence of or history of central nervous system involvement by AML.
Active or previous central nervous system leukemia involvement
Patients who have known central nervous system involvement with multiple myeloma will be excluded from this clinical trial
Active or previous central nervous system leukemia involvement
Central nervous system involvement with MM (by clinical symptoms and signs).
Active involvement of the central nervous system with malignancy
No known history or suspicion of central nervous system involvement by lymphoma
Central nervous system metastases, including leptomeningeal involvement
Known central nervous system involvement with the disease under study
Primary central nervous system involvement only
Patients with known central nervous system involvement should be excluded from this clinical trial
Has known active central nervous system involvement of the malignancy.
Patients with known or suspected central nervous system involvement of lymphoma.
All patients with central nervous system involvement with lymphoma
Known lymphomatous involvement of the central nervous system
History of central nervous system multiple myeloma involvement
Subjects with known central nervous system involvement with multiple myeloma
Active involvement of the central nervous system with malignancy
Known active central nervous system involvement
Central nervous system involvement of the disease under study
Central nervous system involvement
Known lymphomatous involvement of the central nervous system
Known central nervous system involvement
Presence of central nervous system involvement of leukemia or a history of primary central nervous system leukemia.
Patients must not have active central nervous system involvement
Primary central nervous system lymphoma or known intracranial involvement
Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement
Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)
Active involvement of the central nervous system with malignancy
Active involvement of the central nervous system with malignancy
Central nervous system involvement.
Active central nervous system involvement with AML.
Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)
Known active involvement of the central nervous system by lymphoma or leukemia
Known central nervous system involvement by multiple myeloma
Patients with known central nervous system involvement should be excluded from this clinical trial
Central nervous system involvement (Bing-Neel syndrome)
Known involvement of central nervous system
Central nervous system involvement by lymphoma, including leptomeningeal involvement
Clinical evidence of central nervous system involvement.
Known central nervous system involvement or brain metastases
Active central nervous system involvement by leukemia
Active central nervous system involvement
Patients with a history of central nervous system involvement by CLL or who have prolymphocytic leukemia (PLL)
Patients with documented central nervous system involvement of AML
Active central nervous system involvement by malignancy
Documented current central nervous system involvement by multiple myeloma
History of or current, central nervous system involvement with AML.
Known clinically active central nervous system involvement.
Subject has known active central nervous system involvement with AML.
Patients with controlled asymptomatic central nervous system involvement are allowed.
Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease
Subjects with Central Nervous System involvement with multiple myeloma
Central nervous system involvement of the CLL
Active uncontrolled central nervous system involvement
Presence or history of central nervous system involvement by lymphoma.
Patients with known central nervous system involvement at the time of study entry will be excluded from this clinical trial
Primary or secondary Central Nervous System involvement by lymphoma.
Myeloma-related central nervous system involvement
Patients with leukemic involvement of the central nervous system
Central nervous system involvement (based on clinical assessment)
Known clinically active central nervous system involvement
Known active involvement of the central nervous system by lymphoma or leukemia
Central nervous system involvement
Known lymphomatous involvement of the central nervous system.
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)
Active central nervous system involvement by lymphoma
Known central nervous system involvement
Central nervous system involvement.
Known involvement of the central nervous system by WM.
Central nervous system involvement
Patients with a history of central nervous system involvement by lymphoma
Active involvement of the central nervous system with malignancy
Central nervous system disease involvement
Central nervous system involvement
Known Central nervous system involvement, brain metastasis
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required); patients with human T-cell lymphotropic virus type 1 (HTLV1) adult T-cell leukemia/lymphoma (ATLL) and controlled central nervous system (CNS) or meningeal involvement may be enrolled after discussion with the Memorial Sloan Kettering (MSK) principal investigator
Known active central nervous system involvement
Central nervous system involvement.
Presence or history of central nervous system involvement by lymphoma
Known central nervous system involvement by leukemia
No known central nervous system involvement by myeloma.
Disease-related central nervous system involvement
Documented current central nervous system involvement by leukemia or lymphoma
CLL central nervous system involvement
No known involvement of central nervous system by lymphoma
Evidence of sanctuary site involvement by disease, e.g., central nervous system, ocular, testicular involvement
Active involvement of the central nervous system with malignancy
Untreated central nervous system involvement
Known central nervous system involvement
Known central nervous system involvement
Active central nervous system involvement by malignancy; central nervous system disease that has been treated into remission is permitted; a chart note of the clinician’s impression of lack of central nervous system (CNS) involvement is acceptable
Documented current central nervous system involvement
Symptomatic central nervous system involvement
Known uncontrolled central nervous system involvement
Lymphoma involvement of the central nervous system
For Part B only: Known leukemic involvement or clinical symptoms of leukemic involvement of the central nervous system
Central nervous system involvement
Patients with a history of central nervous system involvement by lymphoma
Patients with known central nervous system involvement.
Known, active (symptomatic) involvement of the central nervous system by leukemia.
Known leukemic involvement of the central nervous system.
Documented current central nervous system involvement by leukemia or lymphoma
Central nervous system involvement
Has central nervous system involvement
History of central nervous system involvement of lymphoma;
All patients with active central nervous system involvement with lymphoma
INCLUSION CRITERIA FOR PATIENTS: No central nervous system involvement of disease
Patients with active central nervous system involvement
Symptomatic central nervous system involvement.
History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma
Known central nervous system involvement by multiple myeloma
Known uncontrolled central nervous system involvement by malignant disease
